Adam L Boxer, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 28 years
- New York University School of Medicine, 1998
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Boxer’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A69415 · Current
Licensed to practise in California · since 1999 · expires 2027-08-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,533
Medicare paid this office $4,533 for 30 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 13 | $2,098 | $161 |
| Long return visit (40+ min) | 15 | $1,616 | $101 |
Who their Medicare patients are
30 Original Medicare patients in 2024. Average age 78 · Women 43% · Health risk score 1.07. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 73% · Dementia 67%.
The office billed $32,087, Medicare allowed $6,268 and paid $4,533; for 55 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 30 | 55 | 78 | 1.07 | $32,087 | $4,533 |
| 2023 | 31 | 48 | 75 | 1.18 | $32,996 | $4,552 |
| 2022 | 30 | 49 | 76 | 1.34 | $29,471 | $4,092 |
| 2021 | 30 | 66 | 78 | 1.24 | $34,308 | $4,587 |
| 2020 | 25 | 34 | 75 | 1.44 | $28,410 | $3,727 |
| 2019 | 34 | 40 | 76 | 1.52 | $31,944 | $3,791 |
| 2018 | 39 | 51 | 77 | 1.25 | $32,735 | $4,107 |
| 2017 | 41 | 51 | 76 | 1.28 | $33,473 | $4,292 |
| 2016 | 42 | 55 | 76 | 1.64 | $36,337 | $4,710 |
| 2015 | 42 | 58 | 77 | 1.16 | $35,147 | $4,532 |
| 2014 | 39 | 50 | 77 | 1.11 | $32,627 | $4,320 |
| 2013 | 39 | 46 | 77 | 1.20 | $23,948 | $3,218 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| New patient visit (60+ min) | 15 | $2,271 | $151 |
2022: 1 service
| Long return visit (40+ min) | 11 | $1,143 | $104 |
2021: 3 services
| New patient visit (60+ min) | 14 | $1,695 | $121 |
| Long return visit (40+ min) | 12 | $1,325 | $110 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $899 | $28 |
2020: 1 service
| New patient visit (60+ min) | 14 | $2,124 | $152 |
2019: 1 service
| Long return visit (40+ min) | 16 | $1,557 | $97 |
2018: 2 services
| Long return visit (40+ min) | 14 | $1,421 | $89 |
| Return visit (30+ min) | 16 | $1,160 | $64 |
2017: 2 services
| Long return visit (40+ min) | 17 | $1,571 | $92 |
| Return visit (30+ min) | 18 | $1,041 | $55 |
2016: 3 services
| New patient visit (60+ min) | 12 | $1,791 | $149 |
| Return visit (30+ min) | 22 | $1,410 | $56 |
| Long return visit (40+ min) | 11 | $1,145 | $95 |
2015: 1 service
| Return visit (30+ min) | 24 | $1,486 | $59 |
2014: 3 services
| New patient visit (60+ min) | 12 | $1,722 | $143 |
| Long return visit (40+ min) | 14 | $1,189 | $79 |
| Return visit (30+ min) | 16 | $1,068 | $67 |
2013: 1 service
| Return visit (30+ min) | 14 | $807 | $54 |
Drugs they prescribed that Part D paid
$5,626
Pharmacies billed $5,626 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 65) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
63 generic and fewer than 11 brand-name prescriptions · $5,626 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Donepezil | 16 | $115 | $7 |
| Citalopram Hbr | 12 | $31 | $3 |
Year by year
| 2024 | 65 | 17 | 0% (0) | None | $5,626 |
| 2023 | 61 | 18 | 0% (0) | None | $4,860 |
| 2022 | 77 | 17 | 0% (0) | None | $38,621 |
| 2021 | 69 | 17 | 0% (0) | None | $7,579 |
| 2020 | 79 | 20 | 0% (0) | 0% | $3,773 |
| 2019 | 99 | 28 | 0% (0) | None | $5,138 |
| 2018 | 101 | 30 | 0% (0) | None | $1,535 |
| 2017 | 131 | 29 | 0% (0) | None | $3,230 |
| 2016 | 142 | 28 | 0% (0) | None | $4,009 |
| 2015 | 163 | 29 | 0% (0) | None | $4,754 |
| 2014 | 166 | 29 | 0% (0) | 10% | $7,005 |
| 2013 | 133 | 24 | 0% (0) | 10% | $7,350 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Donepezil | 20 | $524 | $26 |
2022: 2 drugs
| Memantine | 12 | $852 | $71 |
| Donepezil | 21 | $302 | $14 |
2021: 2 drugs
| Memantine | 20 | $1,628 | $81 |
| Donepezil | 18 | $186 | $10 |
2020: 2 drugs
| Memantine | 15 | $648 | $43 |
| Donepezil | 18 | $210 | $12 |
2019: 1 drug
| Donepezil | 32 | $650 | $20 |
2018: 1 drug
| Donepezil | 58 | $829 | $14 |
2017: 2 drugs
| Donepezil | 80 | $833 | $10 |
| Memantine | 17 | $716 | $42 |
2016: 3 drugs
| Memantine | 15 | $1,042 | $69 |
| Donepezil | 76 | $842 | $11 |
| Citalopram Hbr | 16 | $54 | $3 |
2015: 3 drugs
| Donepezil | 85 | $852 | $10 |
| Escitalopram | 24 | $157 | $7 |
| Citalopram Hbr | 23 | $53 | $2 |
2014: 3 drugs
| Donepezil | 87 | $1,682 | $19 |
| Escitalopram | 19 | $355 | $19 |
| Risperidone | 12 | $140 | $12 |
2013: 4 drugs
| Donepezil | 69 | $2,329 | $34 |
| Escitalopram | 18 | $687 | $38 |
| Risperidone | 13 | $305 | $23 |
| Citalopram Hbr | 11 | $74 | $7 |
Money from drug and device companies
$44,601 in 2025
| 2025 | 8 | 35 | $32,356 | $44,601 |
| 2024 | 5 | 12 | $1,500 | $2,074 |
| 2023 | 3 | 18 | $7,525 | $9,544 |
| 2022 | 4 | 18 | $17,430 | $19,941 |
| 2021 | 2 | 4 | $5,820 | $5,820 |
| 2020 | 3 | 6 | $10,535 | $10,585 |
| 2019 | 5 | 27 | $23,670 | $37,429 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Otsuka Pharmaceutical Development & Commercialization | None | $27,718 | 6 payments
|
| Janssen Global Services | None | $9,971 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | None | $3,152 | 3 payments
|
| Janssen Research & Development | None | $2,115 | 1 payment
|
| Biogen | None | $685 | 1 payment
|
| Merck Sharp & Dohme | None | $607 | 2 payments
|
See all 35 published payments
| Janssen Research & Development | Consulting · 2025-12-26 | None | $2,115 |
| Otsuka Pharmaceutical Development & Commercialization | Consulting · 2025-12-10 | None | $8,820 |
| Otsuka Pharmaceutical Development & Commercialization | Consulting · 2025-12-10 | None | $6,804 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-13 | None | $5 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-11-13 | None | $1,044 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-12 | None | $2 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-12 | None | $19 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-12 | None | $44 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-12 | None | $1 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-12 | None | $1 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-11 | None | $86 |
| Otsuka Pharmaceutical Development & Commercialization | Consulting · 2025-11-11 | None | $1,260 |
| Otsuka Pharmaceutical Co. | Meals · 2025-11-10 | None | $38 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-11-10 | None | $645 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-11-10 | None | $9,144 |
| Neurocrine BioSciences | Travel · 2025-10-01 | None | $114 |
| Neurocrine BioSciences | Meals · 2025-09-22 | None | $24 |
| Neurocrine BioSciences | Meals · 2025-09-22 | None | $18 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-08-13 | None | $3,083 |
| Merck Sharp & Dohme | Meals · 2025-07-30 | None | $42 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-26 | None | $47 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-26 | None | $22 |
| Janssen Global Services | Consulting · 2025-07-24 | None | $9,024 |
| Biogen | Consulting · 2025-07-14 | None | $685 |
| Janssen Global Services | Meals · 2025-06-06 | None | $35 |
| Janssen Global Services | Meals · 2025-06-06 | None | $18 |
| Janssen Global Services | Meals · 2025-06-06 | None | $50 |
| Janssen Global Services | Meals · 2025-06-06 | None | $15 |
| Janssen Global Services | Travel · 2025-06-06 | None | $238 |
| Janssen Global Services | Meals · 2025-06-06 | None | $15 |
| Janssen Global Services | Travel · 2025-06-06 | None | $44 |
| Janssen Global Services | Travel · 2025-06-05 | None | $40 |
| Janssen Global Services | Meals · 2025-06-05 | None | $61 |
| Janssen Global Services | Travel · 2025-05-16 | None | $430 |
| Merck Sharp & Dohme | Consulting · 2025-04-01 | None | $565 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,074
| Alexion Pharmaceuticals | None | $1,500 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $267 | 5 payments
|
| Boston Scientific | None | $155 | 3 payments
|
| Eli Lilly and | None | $114 | 2 payments
|
| Ucb Sa | None | $38 | 1 payment
|
2023: $9,544
| Eli Lilly and | None | $6,990 | 16 payments
|
| Pfizer | None | $2,450 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $105 | 1 payment
|
2022: $19,941
| Merck Sharp & Dohme | None | $12,950 | 14 payments
|
| Genentech | None | $2,921 | 2 payments
|
| Genentech USA | None | $2,070 | 1 payment
|
| Boehringer Ingelheim International GmbH | None | $2,000 | 1 payment
|
2021: $5,820
| F. Hoffmann-La Roche AG | None | $4,440 | 2 payments
|
| GlaxoSmithKline | None | $1,380 | 2 payments
|
2020: $10,585
| H. Lundbeck A S | None | $7,395 | 3 payments
|
| Roche Products | None | $2,400 | 2 payments
|
| Regeneron Pharmaceuticals | None | $790 | 1 payment
|
2019: $37,429
| H. Lundbeck A S | None | $29,280 | 8 payments
|
| Eisai | None | $7,345 | 11 payments
|
| UCB Biosciences | None | $500 | 1 payment
|
| Biogen | None | $220 | 5 payments
|
| Boston Scientific | Vercise | $84 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · Prospective Longitudinal Assessment of Imaging and Fluid Biomarkers for Progressive Supranuclear Palsy, A Primary Tauopathy · 2023 | Their institution | $774,935 |
| Biogen, Inc. · 221ad301 Phase 3 Study of Aducanumab (Biib037) in Early Alzheimer'S Disease · 2020 | Their institution | $721,405 |
| Regeneron Pharmaceuticals, Inc. · Prospective Longitudinal Assessment of Imaging and Fluid Biomarkers for Progressive Supranuclear Palsy, A Primary Tauopathy · 2021 | Their institution | $421,731 |
| Biogen, Inc. · A Study To Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies 221ad103, 221ad301, 221ad302 and 221ad205 · 2021 | Their institution | $421,053 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2023 | Their institution | $348,417 |
| Regeneron Pharmaceuticals, Inc. · Prospective Longitudinal Assessment of Imaging and Fluid Biomarkers for Progressive Supranuclear Palsy, A Primary Tauopathy · 2022 | Their institution | $269,823 |
| Biogen, Inc. · 221ad301 Phase 3 Study of Aducanumab (Biib037) in Early Alzheimer'S Disease · 2019 | Their institution | $261,787 |
| Biogen, Inc. · Study of Biib092 in Participants With Progressive Supranuclear Palsy · 2019 | Their institution | $212,032 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2022 | Their institution | $203,304 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2020 | Their institution | $179,256 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2021 | Their institution | $174,062 |
| F. Hoffmann-La Roche AG · Ph Ib Crenezumab Eff Sfy Mild Mod Ad · 2019 | Their institution | $172,615 |
| Genentech, Inc. · Prodromal To Mild Ad · 2019 | Their institution | $160,171 |
| Biogen, Inc. · A Study To Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies 221ad103, 221ad301, 221ad302 and 221ad205 · 2020 | Their institution | $159,527 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2023 | Their institution | $141,148 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2022 | Their institution | $109,617 |
| Biogen, Inc. · Extension Study of Biib092 in Participants With Progressive Supranuclear Palsy (Psp) Who Participated in Cn002003 · 2019 | Their institution | $100,995 |
| Biogen, Inc. · Extension Study of Biib092 in Participants With Progressive Supranuclear Palsy (Psp) Who Participated in Cn002003 · 2020 | Their institution | $89,157 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2024 | Their institution | $78,869 |
| Biogen, Inc. · Study of Biib092 in Participants With Progressive Supranuclear Palsy · 2020 | Their institution | $65,912 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2025 | Their institution | $53,672 |
| Biogen, Inc. · Study of Biib092 in Participants With Progressive Supranuclear Palsy · 2021 | Their institution | $44,924 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2025 | Their institution | $41,407 |
| Biogen, Inc. · Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (Bvftd) · 2019 | Their institution | $38,570 |
| Biogen, Inc. · Extension Study of Biib092 in Participants With Progressive Supranuclear Palsy (Psp) Who Participated in Cn002003 · 2021 | Their institution | $34,745 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2024 | Their institution | $29,650 |
| Biogen, Inc. · Biib092 Steering Committee As Chair · 2019 | This clinician | $13,045 |
| Biogen, Inc. · A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered Biib092 in Patients With Progressive Supranuclear Palsy Who Participated in Study Cn002003 · 2022 | Their institution | $6,158 |
| Genentech, Inc. · Prodromal To Mild Ad · 2021 | Their institution | $5,926 |
| F. Hoffmann-La Roche AG · Ph Ib Crenezumab Eff Sfy Mild Mod Ad · 2020 | Their institution | $3,593 |
| Janssen Research & Development, LLC · Neurofilament Surveillance Project Consortium · 2024 | Their institution | $1,900 |
| Janssen Pharmaceuticals, Inc · Neurofilament Surveillance Project Consortium · 2022 | Their institution | $1,700 |
| Janssen Research & Development, LLC · Neurofilament Surveillance Project Consortium · 2023 | Their institution | $1,400 |
| Janssen Research & Development, LLC · Project Jji-Lycaena · 2024 | Their institution | $900 |
| Eli Lilly and Company · Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study · 2022 | This clinician | $540 |
| Janssen Pharmaceuticals, Inc · Neurofilament Surveillance Project (Nsp) · 2021 | Their institution | $300 |
| Eli Lilly and Company · Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study · 2020 | This clinician | $270 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1841231800
- Licence
- CA A69415California A69415: Current · expires 2027-08-31
- Trained
- New York University School of Medicine, 1998 · 28 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A694150
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-06-09
- NPI last updated
- 2026-07-13
This is when the NPI record was last certified, not a medical board exam.